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| INTRODUC TI ON
Renal transplantation (RT) is the most effective therapeutic treatment for end-stage renal disease. 1 T-cell mediated acute rejection was effectively reduced by immunosuppressants. 2 However, longterm survival rate of allografts and recipients is still limited because of the progressive deterioration of allograft function and (CAD). 3, 4 Kidney interstitial fibrosis, the most important pathological lesion of CAD, was derived from the extracellular matrix deposition caused by activated fibroblasts. 5 Epithelial-mesenchymal transition (EMT), as a source of myofibroblasts, is characterized that epithelial cells are transformed to α-smooth muscle actin (α-SMA) positive myofibroblasts and lose their epithelial markers such as E-cadherin. 6, 7 EMT is regulated by various bio-mediators such as transforming growth factor-beta (TGF-β), Ang II and microRNAs. [8] [9] [10] Our previous research has shown that tumor necrosis factor-alpha (TNF-α) could induce the progression of EMT. HK-2 cells lose the expression of E-cadherin and overexpress α-SMA and fibronectin after the treatment of TNF-α.
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Smad ubiquitination regulatory factor 1 (Smurf1), an E3 ubiquitin ligase, was reported that it was involved in the EMT in lens epithelial explants, breast cancer and chronic kidney diseases (CKD) induced by TGF-β. [12] [13] [14] In recent studies, Smurf1 was reported that it was involved in the fibrosis of diabetic kidneys and obstructive nephropathy. 15, 16 But the role of Smurf1 in the interstitial fibrosis of transplant kidney is still unknown. Depending on these reported findings, we hypothesized that Smurf1 might play a critical role in the transplant kidney interstitial fibrosis caused by EMT.
Bortezomib, a proteasome inhibitor, is used to prevent the production of alloantibody in the treatment of antibody-mediated rejection (ABMR) through the induction of plasma cells apoptosis. 17 It was also reported that could alleviate the fibrosis of skin, lung and CKD stimulated by TGF-β. 18, 19 However, the effect of Bortezomib in the treatment of allograft kidney interstitial fibrosis caused by EMT still remain to be determined. The aim of this study was to investigate the role and the potential molecular mechanisms of Smurf1 in the EMT induced by TNF-α and to detect the anti-fibrogenic effect of Bortezomib. Our results show that Smurf1 plays a critical role in regulating the EMT induced by TNF-α. Bortezomib can attenuate the Sumrf1-mediated progression of EMT and renal allograft interstitial fibrosis.
| MATERIAL S AND ME THODS

| Ethics statement
The study protocol was in accordance with the ethical standards of the Declaration of Helsinki and Istanbul. The study protocol involving human kidney tissues was approved by the local ethics committee of the First Affiliated Hospital of Nanjing Medical University.
Written informed consent was obtained from all transplant recipients and nephrectomy patients.
| Sample collection
Allograft kidney sections were obtained from 30 patients, which were collected from transplanted kidney nephrectomy or kidney biopsy of recipients. All patients, who had undergone kidney transplantation at our centre from January 2001 to October 2017 was diagnosed with CAD according to their allograft biopsy results.
Patients diagnosed with CAD was classified as CAD group. In addition, 25 normal kidney samples obtained from more than 5 cm away from the tumour tissues were collected from radical nephrectomy and considered as control group. The baseline characteristics of patients in the CAD group and control group are given in Table 1 .
| Animals
Adult male F344 and Lewis rats (200-250 g) were procured from Charles River Laboratories (Beijing, China). The animal centre provided the rats with the clean tap water and standard rat chow.
Animal handling procedures were in accordance with guidelines published by the US National Institutes of Health, and animal ethics established by Nanjing Medical University. 
TA B L E 1 Baseline characteristics of the CAD and control groups
| Kidney transplantation
Orthotopic left kidney transplantation was performed between F344 and Lewis rats as previously described. 20 Nephrectomy of the right kidney was performed 10 days after the surgery of the transplantation. The average time of cold ischaemia and warm ischaemia was 30 or 35 minutes, respectively. In case of the acute rejection, cyclosporine A (5 mg/kg bodyweight; Neoral, Novartis, Switzerland) was used once a day intraperitoneally, lasting for 14 days.
| Pharmaceutical treatment and tissue harvest
From the first day after the kidney transplantation, Bortezomib (0.2 mg/kg; Selleck Chemicals, USA) was iv injected to isogeneic or allogeneic recipient rats twice a week.
At 4 weeks, 8 weeks, 12 weeks and 16 weeks, organs were harvested and divided into two parts, which was fixed in paraffin or snap-frozen in N2 and stored at −80°C.
| Enzyme-linked immunosorbent assay
The levels of rat serum TNF-α were quantified by the rat TNF-α ELISA kit (MUTISCIENCES; China). Rat serum and cell culture medium supernatant level of TGF-β1 were quantified by the TGF-β1
ELISA kit (MUTISCIENCES; China). The assays were performed as described in the manufacturer's instruction.
| Histology and morphometry
Histological analysis was performed by using haematoxylin and eosin (H&E) and Masson trichome staining. H&E and Masson trichome staining were performed as detailed elsewhere, which was used to evaluate the severity of chronic kidney rejection and the area of renal interstitial fibrosis separately. 21 Image-Pro Plus (Media Cybernetics, Rockville, MD) was used by two pathologists blinded to the experimental design independently to quantify the morphometric change of the kidney sections.
| Immunohistochemistry
Immunohistochemical staining assays were performed to evaluate the 
| Indirect immunofluorescence doublestaining assay
Immunofluorescence double-staining assay were performed as previously described, using antibodies against TGF-β1 (1:100;
CST, USA), α-SMA (1:200; Abcam, USA), E-cadherin (1:50; BD Biosciences, USA). 21 The fluorescence intensities of TGF-β1, Ecadherin and α-SMA were performed using Image-Pro Plus (Media Cybernetics, USA).
| Renal function assessment
Concentrations of rat blood creatinine and urea nitrogen were tested by instructions of manufacturer of the kits (Jiancheng, Beijing, China).
| Quantitative real-time PCR analysis
Total RNA was extracted from cells with the RNA extraction kits (TIANGEN, Beijing, China). cDNA was synthesized with a
PrimeScriptTMRT reagent kit (TaKaRa Biotechnology, Japan).
qRT-PCR was performed with a SYBR Green PCR kit (TaKaRa Biotechnology) on a DNA Engine Opticon 2 System (BioRad laboratories, Hercules, CA). The specific primers used were as follows:
mRNA expression was normalized to b-actin expression. Every experiment described previously was repeated at least three times.
| Western blot analysis
Western blotting was performed according to the protocol described by Liu et al 22 Total proteins were extracted from cells, human tissues or rat tissues. Then, western blotting was conducted by incubating the protein with primary antibodies. The primary antibodies were as followed: anti-GAPDH (1:1000; CST, USA), anti-E-cadherin 
| Statistical analysis
All data were presented as the mean ± SD values determined from three independent experiments. After demonstration of homogeneity of variance with Bartlett test, inter-group comparisons were made using oneway analysis of variance (ANOVA). Multiple means were compared using Tukey's test. The differences between two groups were determined by Student t test. Values of P < 0.05 were considered statistically significant. All the assays were repeated at least three times independently.
| RE SULTS
| Smurf1 exhibits remarkably high expression in the kidney tissues of renal interstitial fibrosis from CAD patients
In this study, we used human specimens to confirm the high expression of Smurf1 in the CAD patients with allograft renal interstitial 
| Progression of EMT in HK-2 cells could be stimulated by TNF-α
To investigate the pathogenesis of EMT stimulated by TNF-α, we stimulated the HK-2 cells with different concentrations of TNF-α(0,10,20,50 ng/mL) for 24 hours. TNF-α up-regulated the protein and mRNA expression of fibronectin and α-SMA, leading F I G U R E 2 Smurf1 is remarkably increased in the EMT stimulated by TNF-α. TNF-α promotes Smurf1, α-SMA and fibronectin expression and suppresses E-cadherin expression in the HK-2s. Equal amounts of protein from whole cell lysates were analysed by western blotting with antibodies against α-SMA, fibronectin, E-cadherin and GAPDH after stimulation of HK-2s with various concentrations of TNF-α for 24 hours (A) or incubation of HK-2s with 50ng/mL TNF-α for the indicated time points (B). (C-J) HK-2s were stimulated with various concentrations of TNF-α for 24 hours (C-E) or with 50ng/mL TNF-α for the indicated time points(F-J). (I) Representative western blot of Smurf1 indicated protein expression of Smurf1 has remarkably increased when HK-2s was stimulated for 0.5 h. Total RNA was isolated and subjected to quantitative real-time PCR to detect the gene expression of α-SMA, fibronectin, E-cadherin and Smurf1. Relative abundance of mRNAs is presented as the mean ± SD value of three independent experiments. The PCR results were in agreement with the western blot results. *P < 0.05, **P < 0.01, ***P < 0.001 vs the control group vs sh-con cells without TNF-α treatment, f P < 0.05 vs sh-con cells stimulated by TNF-α, g P < 0.05 vs sh-con cells without TNF-α treatment, h P < 0.05 vs sh-con cells stimulated by TNF-α, *P < 0.05 vs sh-con cells or ov-con cells stimulated by TNF-α to a dose-dependent decline in the expression of E-cadherin at the same time (Figure 2A,C-E) . This effect was peaked while the HK-2 cells were treated by 50 ng/mL TNF-α, and was reversed at the concentration of 100 ng/mL TNF-α. Time-dependent studies were performed to confirm that the protein and mRNA expression of fibronectin and α-SMA. This effect was at the peak 
| Smurf1 plays a critical role in the EMT induced by TNF-α
To confirm the role of Smurf1 in the EMT induced by TNF-α, we examined the effect of Smurf1 silencing on these events by constructing Smurf1 stable knockdown HK-2 cells. As shown in the Figure 3A , relative intensity of α-SMA in sh-Smurf1 group stimulated by TNF-α was significantly less than sh-con group according to the outcome of immunofluorescence. However, the relative intensity of E-cadherin was remarkably higher than sh-con group. These data supported our conclusion that Smurf1 plays a critical role in the EMT of HK-2 cells.
| Bortezomib alleviates the Smurf1-meditated EMT of HK-2 cells by inhibiting TNF-α-Akt-mTOR-P70S6K pathway
To evaluate the signalling pathways involved in TNF-α-induced EMT in HK-2 cells, we examined phosphorylation of factors involved in the canonical signalling pathways by western blotting. We observed the activation of the Akt-mTOR-P70S6K signalling pathways when HK-2 cells were treated with TNF-α 
| Bortezomib ameliorates the inflammatory response and renal interstitial fibrosis in rat allograft kidney after transplantation
In this study, we applied Bortezomib to explore the role of the pro- The anti-fibrosis effect of Bortezomib was not only to block the TNF-α-Smurf1-Akt-mTOR-P70S6K pathway by reducing the expression of Smurf1, but also to decrease the secretion of inflammatory cytokines TNF-α ( Figure 6H ).
| Bortezomib prevents allograft renal function impairment and prolongs survival of allogeneic recipients
In order to test the impact of Bortezomib on allograft renal function and long-term survival of allogeneic recipients, the native right kidneys of recipients were removed 2 weeks after left kidney transplantation. One week after the resection of right kidney, the renal function including the blood concentration of creatinine and urea nitrogen, started to be continuously deteriorated until their death.
However, the increase of blood creatinine and urea nitrogen was inhibited and they remained at a relatively low level by the treatment of Bortezomib ( Figure 7A-B) . The survival rate of allogeneic recipients was enhanced by the treatment of Bortezomib ( Figure 7C ).
Allogeneic recipients treated with Bortezomib enjoyed a higher survival rate compared with allo-recipients treated by vehicle at both 12 and 16 weeks.
| D ISCUSS I ON
In present study, we reported that Bortezomib could attenuate the fibrosis of renal interstitial in kidney transplantation via reg- Furthermore, we found the anti-fibrogenic effects of Bortezomib, which alleviated the fibrosis and EMT of HK-2 cells by downregulating the expression of Smurf1. Bortezomib was reported that it prevents oncogenesis and bone metastasis of prostate cancer by inhibiting Smurf1 expression. 24 However, its mechanism of action is not fully understood. miR-424(322) induced the downregulation of Smurf1 in pulmonary arterial hypertension. 25 Bortezomib could modulate various miRNA level such as microRNA-17-5p. 26 The potential mecha- WWP2, another E3 Ubiquitin Ligases, could degrade PTEN by ubiquitination pathway to suppress tumourigenesis. 31 The mechanism that Smurf1 down-regulated the Akt-mTOR-P70S6K pathway could be the degradation of PTEN.
To confirm the anti-fibrogenic effect of Bortezomib, our vivo findings revealed that Bortezomib could reduce the inflammatory response and renal interstitial fibrosis in allograft kidney. Bortezomib 
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